Searchable abstracts of presentations at key conferences in endocrinology

ea0022p566 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Euthyroidism and tumor stability achieved in a TSH-secreting pituitary macroadenoma treated with octreotide-LAR and cabergoline: case report and literature review

Simoes Helder , Lalanda Carolina , Oliveira Manuela , Raposo Luis , Duarte Sequeira , Saraiva Machado

Introduction: TSH-secreting adenomas represent <2% of pituitary tumors. Surgery and/or radiotherapy are primary treatment options. Somatostatin analogues and also dopamine agonists, represent valuable alternatives or adjuvant therapies.Objective: To report a case of euthyroidism and tumor stability achieved in a TSH-secreting pituitary macroadenoma, treated with octreotide-LAR, as first line therapy, and then added cabergoline. To review the efficacy...